Compare Stocks: RPTX, KMDA, INDP, and YDES

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INDP Indaptus Therapeutics	$3.24 -7.4%	$2.59	$0.92 ▼ $5.96	$431.70M	0.97	602,838 shs	111,967 shs
KMDA Kamada	$7.25 -1.5%	$8.18	$6.55 ▼ $9.35	$416.91M	0.9	80,857 shs	322,751 shs
RPTX Repare Therapeutics	$2.65 +0.8%	$2.62	$1.24 ▼ $2.66	$114.24M	0.97	516,093 shs	1.22 million shs
YDES YD Bio	$6.39 +7.0%	$5.15	$1.70 ▼ $15.72	$452.34M	-1.19	144,529 shs	23,343 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INDP Indaptus Therapeutics	+13.78%	+4.79%	+47.06%	+157.35%	+8.70%
KMDA Kamada	-4.42%	-7.30%	-11.43%	+0.27%	+6.36%
RPTX Repare Therapeutics	0.00%	0.00%	0.00%	0.00%	+44.02%
YDES YD Bio	+0.51%	+12.85%	-26.39%	+157.33%	+596,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INDP Indaptus Therapeutics	$3.24 -7.4%	$2.59	$0.92 ▼ $5.96	$431.70M	0.97	602,838 shs	111,967 shs
KMDA Kamada	$7.25 -1.5%	$8.18	$6.55 ▼ $9.35	$416.91M	0.9	80,857 shs	322,751 shs
RPTX Repare Therapeutics	$2.65 +0.8%	$2.62	$1.24 ▼ $2.66	$114.24M	0.97	516,093 shs	1.22 million shs
YDES YD Bio	$6.39 +7.0%	$5.15	$1.70 ▼ $15.72	$452.34M	-1.19	144,529 shs	23,343 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INDP Indaptus Therapeutics	+13.78%	+4.79%	+47.06%	+157.35%	+8.70%
KMDA Kamada	-4.42%	-7.30%	-11.43%	+0.27%	+6.36%
RPTX Repare Therapeutics	0.00%	0.00%	0.00%	0.00%	+44.02%
YDES YD Bio	+0.51%	+12.85%	-26.39%	+157.33%	+596,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INDP Indaptus Therapeutics	1.00	Sell	N/A	N/A
KMDA Kamada	3.00	Buy	$13.50	86.21% Upside
RPTX Repare Therapeutics	1.50	Reduce	N/A	N/A
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RPTX, KMDA, INDP, and YDES Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	INDP Indaptus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/9/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
9/22/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy (B-)
9/18/2026	KMDA Kamada	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$15.00

(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$1.40 per share	N/A
KMDA Kamada	$191.85M	2.17	$0.55 per share	13.10	$4.68 per share	1.55
RPTX Repare Therapeutics	$11.87M	9.62	N/A	N/A	$3.56 per share	0.74
YDES YD Bio	$1.24M	364.99	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INDP Indaptus Therapeutics	-$20.85M	-$6.33	N/A	N/A	N/A	N/A	-302.89%	-203.49%	11/17/2026 (Estimated)
KMDA Kamada	$20.20M	$0.38	19.08	12.50	0.67	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$1.69	N/A	N/A	N/A	N/A	-60.15%	-52.24%	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest RPTX, KMDA, INDP, and YDES Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/17/2026	Q3 2026	INDP Indaptus Therapeutics	-$1.46	N/A	N/A	N/A	N/A	N/A
11/9/2026	Q3 2026	KMDA Kamada	$0.13	N/A	N/A	N/A	$52.51 million	N/A
9/1/2026	Q2 2026	YDES YD Bio	N/A	$0.05	N/A	$0.0450	N/A	$0.42 million
8/13/2026	Q2 2026	INDP Indaptus Therapeutics	-$1.57	-$0.02	+$1.55	-$0.02	N/A	N/A
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.12	1.66%	N/A	31.58%	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Latest RPTX, KMDA, INDP, and YDES Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INDP Indaptus Therapeutics	N/A	19.49	19.49
KMDA Kamada	N/A	4.06	2.29
RPTX Repare Therapeutics	N/A	10.71	10.71
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INDP Indaptus Therapeutics	7.06%
KMDA Kamada	20.38%
RPTX Repare Therapeutics	85.09%
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
INDP Indaptus Therapeutics	9.94%
KMDA Kamada	36.10%
RPTX Repare Therapeutics	11.50%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INDP Indaptus Therapeutics	5	133.24 million	120.00 million	Not Optionable
KMDA Kamada	462	57.51 million	36.75 million	Optionable
RPTX Repare Therapeutics	180	43.11 million	38.15 million	Optionable
YDES YD Bio	14	70.79 million	N/A	N/A

RPTX, KMDA, INDP, and YDES Headlines

Recent News About These Companies

YD Bio (NASDAQ:YDES) Stock Price Crosses Above 200-Day Moving Average - Here's Why

October 28, 2026 | americanbankingnews.com

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

October 20, 2026 | globenewswire.com

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

October 6, 2026 | globenewswire.com

Cours YD Bio Limited

September 24, 2026 | zonebourse.comZ

YD Bio (NASDAQ:YDES) CEO Ethan Phd Shen Purchases 3,100 Shares of Stock

September 11, 2026 | insidertrades.com

中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%

September 1, 2026 | finet.hkF

YD Bio Ltd (YDES)

September 1, 2026 | finance.yahoo.com

YD Bio Files First-Half 2026 Results, Reports Improved Equity Position

September 1, 2026 | tipranks.com

YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million

August 31, 2026 | quiverquant.comQ

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

August 31, 2026 | globenewswire.com

YDES - YD Bio Limited

August 26, 2026 | seekingalpha.com

Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan

August 26, 2026 | zonebourse.comZ

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

August 25, 2026 | globenewswire.com

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...

August 11, 2026 | markets.businessinsider.com

YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem

August 11, 2026 | tipranks.com

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, KMDA, INDP, and YDES Company Descriptions

Indaptus Therapeutics NASDAQ:INDP

$3.24 -0.26 (-7.43%)

Closing price 04:00 PM Eastern

Extended Trading

$3.23 -0.01 (-0.28%)

As of 05:49 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Kamada NASDAQ:KMDA

$7.25 -0.11 (-1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$7.26 +0.00 (+0.07%)

As of 04:10 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Repare Therapeutics NASDAQ:RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

YD Bio NASDAQ:YDES

$6.39 +0.42 (+7.04%)

Closing price 04:00 PM Eastern

Extended Trading

$6.39 0.00 (0.00%)

As of 04:10 PM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RPTX, KMDA, INDP, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RPTX, KMDA, INDP, and YDES Earnings

Compare Dividends

Latest RPTX, KMDA, INDP, and YDES Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPTX, KMDA, INDP, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, KMDA, INDP, and YDES Company Descriptions

Indaptus Therapeutics NASDAQ:INDP

Kamada NASDAQ:KMDA

Repare Therapeutics NASDAQ:RPTX

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RPTX, KMDA, INDP, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RPTX, KMDA, INDP, and YDES Earnings

Compare Dividends

Latest RPTX, KMDA, INDP, and YDES Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPTX, KMDA, INDP, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, KMDA, INDP, and YDES Company Descriptions

Indaptus Therapeutics NASDAQ:INDP

Kamada NASDAQ:KMDA

Repare Therapeutics NASDAQ:RPTX

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools